Effect of anti-fibrotic therapy on regression of myocardial fibrosis after TAVI: design and rationale of the Reduce-MFA DZHK25 trial
ESC Heart Failure · 05.05.2026 · 13 (3)
DOI: 10.1093/eschf/xvag083 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift ESC Heart Failure, online erschienen am 12.05.2026. Verfasst von Miriam Puls und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Pneumology, University Medical Centre Göttingen, Robert-Koch-Straße 40, Göttingen 37075, Germany. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Ventricular Remodeling, Myocardium, Transcatheter Aortic Valve Replacement. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: DZHK, German Research Foundation.
Abstract (Originalsprache)
Aims
Myocardial fibrosis (MF) represents a key player in transition to heart failure in aortic stenosis (AS), and AS patients with high baseline MF are at increased risk to die within 12 months after transcatheter aortic valve implantation (TAVI). Therefore, the objective of the Reduce-MFA DZHK25 trial is to assess the impact of anti-fibrotic therapy on regression of AS-induced MF after TAVI in patients with high baseline fibrotic burden. Key secondary objectives include reverse LV remodelling, symptomatic improvement, and reduction of mortality and cardiac hospitalizations.
Methods
Reduce-MFA represents a national, prospective, randomized, parallel group, controlled, open-label interventional multi-centre trial with blinded outcome assessment (PROBE design) enrolling patients with severe AS scheduled for TAVI. The anti-fibrotic principles employed are spironolactone and low-dose dihydralazine (epigenetic reactivation of anti-fibrotic genes). Baseline burden and course of MF are assessed by cardiac MRI (CMR). Since CMR-derived extracellular volume fraction (ECV%) ≥ 25.9% emerged as independent mortality predictor, only patients above this cut-off are randomized into three parallel groups: (i) Standard of Care alone, (ii) + spironolactone, (iii) + spironolactone + low-dose dihydralazine, each for 12 months. To assess MF regression, CMR is repeated after 12 months. MF is assessed by quantification of the ECV-derived LV matrix volume using T1 mapping. Additionally, measures of heart failure (Kansas City Cardiomyopathies Quality of Life Questionnaire, 6MWT, NT-proBNP, NYHA class) and reverse cardiac remodelling are evaluated at 6 and 12 months. Mortality and cardiac hospitalizations are recorded. The recruitment was recently completed with 384 enrolled and 153 randomized patients.
Conclusions
The study findings have the potential to inform the development of a novel adjuvant therapy to improve the prognosis of specific AS patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology and Pneumology, University Medical Centre Göttingen, Robert-Koch-Straße 40, Göttingen 37075, Germany.
- German Centre for Cardiovascular Research (DZHK), partner site Lower Saxony, Robert-Koch-Straße 40, Göttingen 37075, Germany.
- Department of Medical Statistics, University Medical Centre Göttingen, Göttingen 37073, Germany.
- Clinical Trials Unit, University Medical Centre Göttingen, Göttingen 37075, Germany.
- Department of Clinical Chemistry, University Medical Centre Göttingen, Göttingen 37075, Germany.
- FORUM Medicine, Cardiology, Rosdorf 37124, Germany.
ORCID-Profile: Miriam Puls, Torben Lange, Tim Friede
Förderung
- DZHK
- German Research Foundation
Zitieren
APA
Puls, M., Zeisberg, E. M., Placzek, M., Beuthner, B. E., Jacob, C. F., Steinhaus, K. E., Lange, T., Tostmann, R., Schnelle, M., Schuster, A., Hasenfuß, G., & Friede, T. (2026). Effect of anti-fibrotic therapy on regression of myocardial fibrosis after TAVI: design and rationale of the Reduce-MFA DZHK25 trial. ESC Heart Failure, 13(3). https://doi.org/10.1093/eschf/xvag083
Vancouver
Puls M, Zeisberg EM, Placzek M, Beuthner BE, Jacob CF, Steinhaus KE, et al. Effect of anti-fibrotic therapy on regression of myocardial fibrosis after TAVI: design and rationale of the Reduce-MFA DZHK25 trial. ESC Heart Failure. 2026;13(3). doi:10.1093/eschf/xvag083
BibTeX
@article{Puls2026,
author = {Puls, Miriam and Zeisberg, Elisabeth M and Placzek, Marius and Beuthner, Bo E and Jacob, Christoph F and Steinhaus, Kristin E and Lange, Torben and Tostmann, Ralf and Schnelle, Moritz and Schuster, Andreas and Hasenfuß, Gerd and Friede, Tim},
title = {Effect of anti-fibrotic therapy on regression of myocardial fibrosis after TAVI: design and rationale of the Reduce-MFA DZHK25 trial},
journal = {ESC Heart Failure},
year = {2026},
volume = {13},
number = {3},
doi = {10.1093/eschf/xvag083}
}
EUVIMED